<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01229267</url>
  </required_header>
  <id_info>
    <org_study_id>V212-001</org_study_id>
    <secondary_id>2010-020150-34</secondary_id>
    <secondary_id>V212-001</secondary_id>
    <nct_id>NCT01229267</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)</brief_title>
  <official_title>A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study to assess the safety and
      efficacy of inactivated VZV vaccine for the prevention of HZ and HZ-related complications in
      adult recipients of autologous hematopoietic cell transplants (HCTs). The primary hypothesis
      is that vaccination with V212 vaccine will reduce the incidence of herpes zoster (HZ)
      compared to placebo when administered to recipients of HCT. The statistical criterion for
      success requires that the lower bound of the 95% confidence interval for the estimated
      vaccine efficacy in the V212 recipients (excluding the high-antigen lot) compared with that
      in the placebo recipients is &gt;25%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants were randomized to receive one of 3 consistency lots of V212, a high
      antigen lot of V212, or placebo. To comply with regulatory requests, results for all lots of
      V212 were combined for the primary and secondary efficacy and safety evaluations (Protocol
      Amendment 2); all planned comparisons between the V212 lots were exploratory and are not
      included in this disclosure. Further, by regulatory request, the V212 High Antigen Lot was
      not included in the efficacy analyses for concerns that its inclusion would inflate the
      efficacy estimates (Protocol Amendment 4).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2010</start_date>
  <completion_date type="Actual">December 23, 2015</completion_date>
  <primary_completion_date type="Actual">December 23, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Confirmed Herpes-Zoster</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Clinical criteria for suspected Herpes-Zoster (HZ) cases were the development of a papular or vesicular rash with a dermatomal or generalized distribution, or in the absence of a rash, clinical suspicion of VZV infection with or without the detection of VZV in diagnostic specimens from blood, cerebrospinal fluid, lung, liver, or other organ. All suspected cases of HZ were subjected to adjudication by the Clinical Adjudication Committee (CAC). Case confirmation was based on skin lesion polymerase chain reaction, if available, or by adjudication of the clinical case description by the CAC, conducted according to the CAC Standard Operations Procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With One or More Serious Adverse Events</measure>
    <time_frame>Up to 28 days after vaccination 4 (up to 118 days)</time_frame>
    <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Moderate to Severe Herpes-Zoster-Associated Pain</measure>
    <time_frame>Up to 6 months after onset of HZ (up to approximately 5 years)</time_frame>
    <description>Moderate to severe HZ-associated pain was defined as 2 or more occurrences of a score 3 or greater (0-to-10 scale, where 0 is no pain and 10 is pain as bad as you can imagine) on the Zoster Brief Pain Inventory (ZBPI) at any time from HZ onset through the end of the 6 month HZ-follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Herpes-Zoster Complications</measure>
    <time_frame>Up to 6 months after onset of HZ (up to approximately 5 years)</time_frame>
    <description>The composite efficacy endpoint of the incidence of HZ complications was defined as the occurrence of any of the following during the study: hospitalization or prolongation of hospitalization due to HZ, disseminated HZ (including disseminated HZ rash or VZV viremia), visceral HZ, ophthalmic HZ, neurological impairment due to HZ, or administration of intravenous acyclovir therapy for treatment of HZ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Postherpetic Neuralgia</measure>
    <time_frame>Up to 6 months after the onset of HZ rash (up to approximately 5 years)</time_frame>
    <description>Postherpetic Neuralgia (PHN) was defined as pain in the area of the HZ rash with pain in the last 24 hours scored as 3 or greater (on a 0 to 10 scale, where 0 is no pain and 10 is pain as bad as you can imagine) on the ZBPI that persists or appears greater than or equal to 90 days after HZ rash onset.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Study Medication Withdrawn Due to an Adverse Event</measure>
    <time_frame>Up to 28 days after vaccination 4 (up to 118 days)</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1257</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>V212 Consistency Lot 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive V212 consistency Lot 1 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V212 Consistency Lot 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive V212 consistency Lot 2 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V212 Consistency Lot 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive V212 consistency Lot 3 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V212 High Antigen Lot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive V212 High Antigen Lot given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V212</intervention_name>
    <description>V212 viral antigen for HZ. Participants will receive consistency Lot 1, 2, or 3 or the High Antigen Lot.</description>
    <arm_group_label>V212 Consistency Lot 1</arm_group_label>
    <arm_group_label>V212 Consistency Lot 2</arm_group_label>
    <arm_group_label>V212 Consistency Lot 3</arm_group_label>
    <arm_group_label>V212 High Antigen Lot</arm_group_label>
    <other_name>Inactivated Varicella-Zoster (VZV) vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Vaccine stabilizer for V212 with no virus antigen</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has prior history of varicella, antibodies to VZV (documented prior to receipt of
             blood products), or residence in a country with endemic VZV infection for ≥30 years or
             if participant is &lt;30 years old, attended primary or secondary school in a country
             with endemic VZV infection.

          -  Scheduled to undergo an autologous hematopoietic cell transplant within 60 days of
             enrollment

          -  Is highly unlikely to conceive during the time period starting 2 weeks prior to
             enrollment through 6 months from last vaccination dose

          -  Female participants of childbearing potential must have a negative serum or urine

        pregnancy test.

        Exclusion Criteria:

          -  History of hypersensitivity reaction to any vaccine component

          -  Prior history of herpes zoster within 1 year of enrollment

          -  Prior receipt of any varicella or zoster vaccine

          -  More than 2 relapses of the underlying cancer (participants with Hodgkin's lymphoma
             may have had more than 2 relapses)

          -  Expectation of tandem transplant procedure

          -  Is expected to receive &gt;6 months (&gt;180 days) of prophylactic antiviral therapy
             post-HCT.

          -  Is pregnant or breastfeeding or expecting to conceive within the period of 2 weeks
             prior to enrollment through 6 months from last vaccination dose.

          -  Has received a live virus vaccine or is scheduled to receive a live virus vaccine in
             the period from 4 weeks prior to Dose 1 through 28 days Postdose 4.

          -  Has received an inactivated vaccine or is scheduled to receive an inactivated vaccine
             in the period between 7 days prior to and 28 days following Doses 1 through 4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Ecuador</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 25, 2010</study_first_submitted>
  <study_first_submitted_qc>October 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2010</study_first_posted>
  <results_first_submitted>April 16, 2018</results_first_submitted>
  <results_first_submitted_qc>June 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2018</results_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herpes zoster</keyword>
  <keyword>vaccine</keyword>
  <keyword>herpes zoster-related complications</keyword>
  <keyword>immunocompromised</keyword>
  <keyword>autologous hematopoietic cell transplants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult participants scheduled to undergo Autologous Hematopoietic Cell Transplant (auto-HCT) within 60 days were enrolled at 150 sties</recruitment_details>
      <pre_assignment_details>A total of 1323 participants were screened and 1257 were randomized. Twenty-seven randomized participants were removed from all analyses due to the identification of major Good Clinical Practice compliance issues at a single site.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>V212 Consistency Lot 1</title>
          <description>Participants randomized to receive V212 consistency Lot 1 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
        </group>
        <group group_id="P2">
          <title>V212 Consistency Lot 2</title>
          <description>Participants randomized to receive V212 Consistency Lot 2 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
        </group>
        <group group_id="P3">
          <title>V212 Consistency Lot 3</title>
          <description>Participants randomized to receive V212 Consistency Lot 3 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
        </group>
        <group group_id="P4">
          <title>V212 High Antigen Lot</title>
          <description>Participants randomized to receive V212 High Antigen Lot given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="184"/>
                <participants group_id="P3" count="187"/>
                <participants group_id="P4" count="106"/>
                <participants group_id="P5" count="564"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 1</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="180"/>
                <participants group_id="P3" count="186"/>
                <participants group_id="P4" count="104"/>
                <participants group_id="P5" count="556"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 2</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="168"/>
                <participants group_id="P4" count="94"/>
                <participants group_id="P5" count="511"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 3</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="155"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="89"/>
                <participants group_id="P5" count="491"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 4</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="149"/>
                <participants group_id="P3" count="149"/>
                <participants group_id="P4" count="87"/>
                <participants group_id="P5" count="477"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="101"/>
                <participants group_id="P4" count="71"/>
                <participants group_id="P5" count="344"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="86"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="220"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="103"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 1257 participants were enrolled. Twenty-seven participants were excluded from the analysis due to Good Clinical Practice non-compliance at a single site.</population>
      <group_list>
        <group group_id="B1">
          <title>V212 Consistency Lot 1</title>
          <description>Participants randomized to receive V212 consistency Lot 1 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
        </group>
        <group group_id="B2">
          <title>V212 Consistency Lot 2</title>
          <description>Participants randomized to receive V212 Consistency Lot 2 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
        </group>
        <group group_id="B3">
          <title>V212 Consistency Lot 3</title>
          <description>Participants randomized to receive V212 Consistency Lot 3 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
        </group>
        <group group_id="B4">
          <title>V212 High Antigen Lot</title>
          <description>Participants randomized to receive V212 High Antigen Lot given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="189"/>
            <count group_id="B2" value="184"/>
            <count group_id="B3" value="187"/>
            <count group_id="B4" value="106"/>
            <count group_id="B5" value="564"/>
            <count group_id="B6" value="1230"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="12.8"/>
                    <measurement group_id="B2" value="54.2" spread="12.6"/>
                    <measurement group_id="B3" value="53.4" spread="12.4"/>
                    <measurement group_id="B4" value="54.3" spread="12.2"/>
                    <measurement group_id="B5" value="54.1" spread="12.2"/>
                    <measurement group_id="B6" value="54.1" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="204"/>
                    <measurement group_id="B6" value="455"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="126"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="360"/>
                    <measurement group_id="B6" value="775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>From 18-49 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="159"/>
                    <measurement group_id="B6" value="346"/>
                  </measurement_list>
                </category>
                <category>
                  <title>From 50-59 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="187"/>
                    <measurement group_id="B6" value="407"/>
                  </measurement_list>
                </category>
                <category>
                  <title>From 60-69 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="188"/>
                    <measurement group_id="B6" value="408"/>
                  </measurement_list>
                </category>
                <category>
                  <title>From 70-79 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intended duration of antiviral prophylaxis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>≤3 months post auto-HCT</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="255"/>
                    <measurement group_id="B6" value="537"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;3 to ≤6 months post auto-HCT</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="308"/>
                    <measurement group_id="B6" value="691"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Confirmed Herpes-Zoster</title>
        <description>Clinical criteria for suspected Herpes-Zoster (HZ) cases were the development of a papular or vesicular rash with a dermatomal or generalized distribution, or in the absence of a rash, clinical suspicion of VZV infection with or without the detection of VZV in diagnostic specimens from blood, cerebrospinal fluid, lung, liver, or other organ. All suspected cases of HZ were subjected to adjudication by the Clinical Adjudication Committee (CAC). Case confirmation was based on skin lesion polymerase chain reaction, if available, or by adjudication of the clinical case description by the CAC, conducted according to the CAC Standard Operations Procedure.</description>
        <time_frame>Up to approximately 5 years</time_frame>
        <population>The population included participants who received ≥1 dose and had auto-HCT. To comply with regulatory requests, results for the V212 consistency lots were combined for the efficacy analyses, and the V212 High Antigen Lot was not included in the efficacy analyses for concerns that its inclusion would inflate efficacy estimates.</population>
        <group_list>
          <group group_id="O1">
            <title>V212 Consistency Lots</title>
            <description>Participants randomized to receive V212 consistency Lot 1, 2, or 3 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Confirmed Herpes-Zoster</title>
          <description>Clinical criteria for suspected Herpes-Zoster (HZ) cases were the development of a papular or vesicular rash with a dermatomal or generalized distribution, or in the absence of a rash, clinical suspicion of VZV infection with or without the detection of VZV in diagnostic specimens from blood, cerebrospinal fluid, lung, liver, or other organ. All suspected cases of HZ were subjected to adjudication by the Clinical Adjudication Committee (CAC). Case confirmation was based on skin lesion polymerase chain reaction, if available, or by adjudication of the clinical case description by the CAC, conducted according to the CAC Standard Operations Procedure.</description>
          <population>The population included participants who received ≥1 dose and had auto-HCT. To comply with regulatory requests, results for the V212 consistency lots were combined for the efficacy analyses, and the V212 High Antigen Lot was not included in the efficacy analyses for concerns that its inclusion would inflate efficacy estimates.</population>
          <units>Number of cases per 1000 person years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.889" lower_limit="23.703" upper_limit="44.456"/>
                    <measurement group_id="O2" value="91.883" lower_limit="75.725" upper_limit="110.469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy was calculated as 1 minus the hazard ratio of HZ in the V212 consistency lot group versus the placebo group. The success criterion for vaccine efficacy required that the lower bound of the 95% confidence interval (CI) is &gt;0.25.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>0.638</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.484</ci_lower_limit>
            <ci_upper_limit>0.746</ci_upper_limit>
            <estimate_desc>Point estimate and 95% CI of vaccine efficacy were obtained from a Cox proportional hazards regression model, adjusting for age (&lt;50 versus ≥50 years of age), and intended duration of antiviral prophylaxis (≤3 versus 3 to 6 months after auto-HCT).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Moderate to Severe Herpes-Zoster-Associated Pain</title>
        <description>Moderate to severe HZ-associated pain was defined as 2 or more occurrences of a score 3 or greater (0-to-10 scale, where 0 is no pain and 10 is pain as bad as you can imagine) on the Zoster Brief Pain Inventory (ZBPI) at any time from HZ onset through the end of the 6 month HZ-follow-up period.</description>
        <time_frame>Up to 6 months after onset of HZ (up to approximately 5 years)</time_frame>
        <population>The population included participants who received ≥1 dose and had auto-HCT. To comply with regulatory requests, results for the V212 consistency lots were combined for the efficacy analyses, and the V212 High Antigen Lot was not included in the efficacy analyses for concerns that its inclusion would inflate efficacy estimates.</population>
        <group_list>
          <group group_id="O1">
            <title>V212 Consistency Lots</title>
            <description>Participants randomized to receive V212 consistency Lot 1, 2, or 3 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Moderate to Severe Herpes-Zoster-Associated Pain</title>
          <description>Moderate to severe HZ-associated pain was defined as 2 or more occurrences of a score 3 or greater (0-to-10 scale, where 0 is no pain and 10 is pain as bad as you can imagine) on the Zoster Brief Pain Inventory (ZBPI) at any time from HZ onset through the end of the 6 month HZ-follow-up period.</description>
          <population>The population included participants who received ≥1 dose and had auto-HCT. To comply with regulatory requests, results for the V212 consistency lots were combined for the efficacy analyses, and the V212 High Antigen Lot was not included in the efficacy analyses for concerns that its inclusion would inflate efficacy estimates.</population>
          <units>Number of cases per 1000 person years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.878" lower_limit="8.958" upper_limit="23.234"/>
                    <measurement group_id="O2" value="49.601" lower_limit="37.941" upper_limit="63.714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy was calculated as 1 minus the hazard ratio of HZ in the V212 consistency lot group versus the placebo group. The success criterion for vaccine efficacy required that the lower bound of the 95% CI is &gt;0.25.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>0.695</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.490</ci_lower_limit>
            <ci_upper_limit>0.818</ci_upper_limit>
            <estimate_desc>Point estimate and 95% CI of vaccine efficacy were obtained from a Cox proportional hazards regression model, adjusting for age (&lt;50 versus ≥50 years of age), and intended duration of antiviral prophylaxis (≤3 versus 3 to 6 months after auto-HCT).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Herpes-Zoster Complications</title>
        <description>The composite efficacy endpoint of the incidence of HZ complications was defined as the occurrence of any of the following during the study: hospitalization or prolongation of hospitalization due to HZ, disseminated HZ (including disseminated HZ rash or VZV viremia), visceral HZ, ophthalmic HZ, neurological impairment due to HZ, or administration of intravenous acyclovir therapy for treatment of HZ.</description>
        <time_frame>Up to 6 months after onset of HZ (up to approximately 5 years)</time_frame>
        <population>The population included participants who received ≥1 dose and had auto-HCT. To comply with regulatory requests, results for the V212 consistency lots were combined for the efficacy analyses, and the V212 High Antigen Lot was not included in the efficacy analyses for concerns that its inclusion would inflate efficacy estimates.</population>
        <group_list>
          <group group_id="O1">
            <title>V212 Consistency Lots</title>
            <description>Participants randomized to receive V212 consistency Lot 1, 2, or 3 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Herpes-Zoster Complications</title>
          <description>The composite efficacy endpoint of the incidence of HZ complications was defined as the occurrence of any of the following during the study: hospitalization or prolongation of hospitalization due to HZ, disseminated HZ (including disseminated HZ rash or VZV viremia), visceral HZ, ophthalmic HZ, neurological impairment due to HZ, or administration of intravenous acyclovir therapy for treatment of HZ.</description>
          <population>The population included participants who received ≥1 dose and had auto-HCT. To comply with regulatory requests, results for the V212 consistency lots were combined for the efficacy analyses, and the V212 High Antigen Lot was not included in the efficacy analyses for concerns that its inclusion would inflate efficacy estimates.</population>
          <units>Number of cases per 1000 person years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.397" lower_limit="4.855" upper_limit="16.414"/>
                    <measurement group_id="O2" value="35.777" lower_limit="25.996" upper_limit="48.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy was calculated as 1 minus the hazard ratio of HZ in the V212 consistency lot group versus the placebo group. The success criterion for vaccine efficacy required that the lower bound of the 95% CI is &gt;0.25.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>0.735</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.498</ci_lower_limit>
            <ci_upper_limit>0.860</ci_upper_limit>
            <estimate_desc>Point estimate and 95% CI of vaccine efficacy were obtained from a Cox proportional hazards regression model, adjusting for age (&lt;50 versus ≥50 years of age), and intended duration of antiviral prophylaxis (≤3 versus 3 to 6 months after auto-HCT).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Postherpetic Neuralgia</title>
        <description>Postherpetic Neuralgia (PHN) was defined as pain in the area of the HZ rash with pain in the last 24 hours scored as 3 or greater (on a 0 to 10 scale, where 0 is no pain and 10 is pain as bad as you can imagine) on the ZBPI that persists or appears greater than or equal to 90 days after HZ rash onset.</description>
        <time_frame>Up to 6 months after the onset of HZ rash (up to approximately 5 years)</time_frame>
        <population>The population included participants who received ≥1 dose and had auto-HCT. To comply with regulatory requests, results for the V212 consistency lots were combined for the efficacy analyses, and the V212 High Antigen Lot was not included in the efficacy analyses for concerns that its inclusion would inflate efficacy estimates.</population>
        <group_list>
          <group group_id="O1">
            <title>V212 Consistency Lots</title>
            <description>Participants randomized to receive V212 consistency Lot 1, 2, or 3 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Postherpetic Neuralgia</title>
          <description>Postherpetic Neuralgia (PHN) was defined as pain in the area of the HZ rash with pain in the last 24 hours scored as 3 or greater (on a 0 to 10 scale, where 0 is no pain and 10 is pain as bad as you can imagine) on the ZBPI that persists or appears greater than or equal to 90 days after HZ rash onset.</description>
          <population>The population included participants who received ≥1 dose and had auto-HCT. To comply with regulatory requests, results for the V212 consistency lots were combined for the efficacy analyses, and the V212 High Antigen Lot was not included in the efficacy analyses for concerns that its inclusion would inflate efficacy estimates.</population>
          <units>Number of cases per 1000 person years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.349" lower_limit="0.484" upper_limit="6.865"/>
                    <measurement group_id="O2" value="14.636" lower_limit="8.674" upper_limit="23.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy was calculated as 1 minus the hazard ratio of HZ in the V212 consistency lot group versus the placebo group. The success criterion for vaccine efficacy required that the lower bound of the 95% CI is &gt;0.25.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>0.837</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.446</ci_lower_limit>
            <ci_upper_limit>0.952</ci_upper_limit>
            <estimate_desc>Point estimate and 95% CI of vaccine efficacy were obtained from a Cox proportional hazards regression model, adjusting for age (&lt;50 versus ≥50 years of age), and intended duration of antiviral prophylaxis (≤3 versus 3 to 6 months after auto-HCT).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With One or More Serious Adverse Events</title>
        <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event.</description>
        <time_frame>Up to 28 days after vaccination 4 (up to 118 days)</time_frame>
        <population>The population included all participants who received ≥1 dose and had safety follow-up. To comply with regulatory requests, results for all lots of V212 were combined in the primary and secondary safety analyses. One participant randomized to placebo was cross-treated; this participant was excluded from the safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>All V212 (Including High Antigen Lot)</title>
            <description>V212 (all lots, including High Antigen Lot) administered by subcutaneous injection 30 days before and 30, 60, and 90 days after auto-HCT.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Serious Adverse Events</title>
          <description>An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event.</description>
          <population>The population included all participants who received ≥1 dose and had safety follow-up. To comply with regulatory requests, results for all lots of V212 were combined in the primary and secondary safety analyses. One participant randomized to placebo was cross-treated; this participant was excluded from the safety analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="657"/>
                <count group_id="O2" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9"/>
                    <measurement group_id="O2" value="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.942</p_value>
            <method>Normal approximation</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
            <estimate_desc>Miettinen &amp; Nurminen</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Study Medication Withdrawn Due to an Adverse Event</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event.</description>
        <time_frame>Up to 28 days after vaccination 4 (up to 118 days)</time_frame>
        <population>The population included all participants who received ≥1 dose and had safety follow-up. To comply with regulatory requests, results for all lots of V212 were combined in the primary and secondary safety analyses. One participant randomized to placebo was cross-treated; this participant was excluded from the safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>All V212 (Including High Antigen Lot)</title>
            <description>V212 (all lots, including High Antigen Lot) administered by subcutaneous injection 30 days before and 30, 60, and 90 days after auto-HCT.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Study Medication Withdrawn Due to an Adverse Event</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event.</description>
          <population>The population included all participants who received ≥1 dose and had safety follow-up. To comply with regulatory requests, results for all lots of V212 were combined in the primary and secondary safety analyses. One participant randomized to placebo was cross-treated; this participant was excluded from the safety analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="657"/>
                <count group_id="O2" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected up to approximately 5 years after vaccination 1.</time_frame>
      <desc>The population included all participants who received ≥1 dose and had safety follow-up. To comply with regulatory requests, results for all lots of V212 were combined in the primary and secondary safety analyses. One participant randomized to placebo was cross-treated; this participant was excluded from the safety analyses.</desc>
      <group_list>
        <group group_id="E1">
          <title>V212 [Including High Antigen Lot]</title>
          <description>Participants received V212 Consistency Lot 1, 2, 3 or High Antigen Lot 0.5 mL administered by subcutaneous injection 30 days before and 30, 60, and 90 days after auto-HCT.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="420" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="374" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Acquired haemophilia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Anaemia megaloblastic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="44" subjects_affected="42" subjects_at_risk="657"/>
                <counts group_id="E2" events="47" subjects_affected="38" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Heparin-induced thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Methaemoglobinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="657"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="657"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cardiac amyloidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="657"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Intraocular haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Anal incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="657"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Dyskinesia oesophageal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Mesenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pancreatic insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="657"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="657"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="657"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="33" subjects_at_risk="657"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cholelithiasis obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Granulomatous liver disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute graft versus host disease in skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Amyloidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Engraftment syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in gastrointestinal tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in liver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Primary amyloidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Actinomycotic pulmonary infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Aspergilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="657"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="657"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="657"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cholangitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis B</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="657"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Coxsackie viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Fungal oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="657"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Gastrointestinal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Infected lymphocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Infection in an immunocompromised host</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="657"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Meningitis pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis herpetic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="74" subjects_affected="61" subjects_at_risk="657"/>
                <counts group_id="E2" events="67" subjects_affected="56" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumonia parainfluenzae viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pulmonary mycosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Retinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="657"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="657"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis septic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="657"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="657"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Viral sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Wound infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Allergic transfusion reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Delayed engraftment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Peroneal nerve injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Transplant dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Traumatic haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Tetany</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Acute promyelocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Anaplastic large cell lymphoma T- and null-cell types</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Anaplastic large cell lymphoma T- and null-cell types recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Anaplastic large-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Angiocentric lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Angioimmunoblastic T-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma stage IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="657"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="657"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma refractory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Extranodal marginal zone B-cell lymphoma (MALT type) recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Follicle centre lymphoma, follicular grade I, II, III recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="657"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease nodular sclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease recurrent</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="657"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Langerhans' cell histiocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Leukaemia recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="657"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Lymphoplasmacytoid lymphoma/immunocytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Malignant lymphoid neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma recurrent</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="657"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma recurrent</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="657"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma refractory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Nonkeratinising carcinoma of nasopharynx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Paraneoplastic syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pericardial effusion malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Peripheral T-cell lymphoma unspecified</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Peripheral T-cell lymphoma unspecified recurrent</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="75" subjects_affected="67" subjects_at_risk="657"/>
                <counts group_id="E2" events="57" subjects_affected="51" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma recurrent</sub_title>
                <counts group_id="E1" events="51" subjects_affected="50" subjects_at_risk="657"/>
                <counts group_id="E2" events="56" subjects_affected="53" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Plasmablastic lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Precursor T-lymphoblastic lymphoma/leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Precursor T-lymphoblastic lymphoma/leukaemia recurrent</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Primary mediastinal large B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Rectal cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Small cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Tumour flare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Intracranial venous sinus thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="657"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="657"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="657"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired phimosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Idiopathic pneumonia syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="657"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Restrictive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="657"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="657"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Venoocclusive disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="657"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="657"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="625" subjects_at_risk="657"/>
                <counts group_id="E2" subjects_affected="512" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="201" subjects_affected="175" subjects_at_risk="657"/>
                <counts group_id="E2" events="168" subjects_affected="134" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="191" subjects_affected="184" subjects_at_risk="657"/>
                <counts group_id="E2" events="138" subjects_affected="135" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="33" subjects_at_risk="657"/>
                <counts group_id="E2" events="41" subjects_affected="32" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="187" subjects_affected="163" subjects_at_risk="657"/>
                <counts group_id="E2" events="157" subjects_affected="129" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="64" subjects_affected="63" subjects_at_risk="657"/>
                <counts group_id="E2" events="54" subjects_affected="53" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="289" subjects_affected="238" subjects_at_risk="657"/>
                <counts group_id="E2" events="264" subjects_affected="212" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="45" subjects_at_risk="657"/>
                <counts group_id="E2" events="35" subjects_affected="34" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="103" subjects_affected="87" subjects_at_risk="657"/>
                <counts group_id="E2" events="81" subjects_affected="78" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="657"/>
                <counts group_id="E2" events="35" subjects_affected="34" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="120" subjects_affected="107" subjects_at_risk="657"/>
                <counts group_id="E2" events="113" subjects_affected="102" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="492" subjects_affected="394" subjects_at_risk="657"/>
                <counts group_id="E2" events="396" subjects_affected="341" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="65" subjects_affected="61" subjects_at_risk="657"/>
                <counts group_id="E2" events="52" subjects_affected="47" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="452" subjects_affected="370" subjects_at_risk="657"/>
                <counts group_id="E2" events="391" subjects_affected="319" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="94" subjects_affected="83" subjects_at_risk="657"/>
                <counts group_id="E2" events="56" subjects_affected="51" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="265" subjects_affected="211" subjects_at_risk="657"/>
                <counts group_id="E2" events="260" subjects_affected="200" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="77" subjects_affected="72" subjects_at_risk="657"/>
                <counts group_id="E2" events="68" subjects_affected="60" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="44" subjects_affected="39" subjects_at_risk="657"/>
                <counts group_id="E2" events="42" subjects_affected="35" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="159" subjects_affected="144" subjects_at_risk="657"/>
                <counts group_id="E2" events="131" subjects_affected="121" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="323" subjects_affected="153" subjects_at_risk="657"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="283" subjects_affected="133" subjects_at_risk="657"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="52" subjects_affected="35" subjects_at_risk="657"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="257" subjects_affected="124" subjects_at_risk="657"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="271" subjects_affected="254" subjects_at_risk="657"/>
                <counts group_id="E2" events="244" subjects_affected="226" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="89" subjects_affected="77" subjects_at_risk="657"/>
                <counts group_id="E2" events="72" subjects_affected="65" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="526" subjects_affected="317" subjects_at_risk="657"/>
                <counts group_id="E2" events="374" subjects_affected="248" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="161" subjects_affected="152" subjects_at_risk="657"/>
                <counts group_id="E2" events="150" subjects_affected="132" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="33" subjects_at_risk="657"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="65" subjects_affected="55" subjects_at_risk="657"/>
                <counts group_id="E2" events="45" subjects_affected="40" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="165" subjects_affected="141" subjects_at_risk="657"/>
                <counts group_id="E2" events="135" subjects_affected="111" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="88" subjects_affected="76" subjects_at_risk="657"/>
                <counts group_id="E2" events="75" subjects_affected="62" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="41" subjects_at_risk="657"/>
                <counts group_id="E2" events="42" subjects_affected="40" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="63" subjects_affected="56" subjects_at_risk="657"/>
                <counts group_id="E2" events="51" subjects_affected="46" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="35" subjects_affected="33" subjects_at_risk="657"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="46" subjects_affected="44" subjects_at_risk="657"/>
                <counts group_id="E2" events="51" subjects_affected="46" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="657"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="149" subjects_affected="131" subjects_at_risk="657"/>
                <counts group_id="E2" events="141" subjects_affected="114" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="38" subjects_affected="35" subjects_at_risk="657"/>
                <counts group_id="E2" events="32" subjects_affected="31" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="91" subjects_affected="84" subjects_at_risk="657"/>
                <counts group_id="E2" events="71" subjects_affected="68" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="84" subjects_affected="76" subjects_at_risk="657"/>
                <counts group_id="E2" events="93" subjects_affected="80" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="60" subjects_affected="55" subjects_at_risk="657"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="48" subjects_affected="41" subjects_at_risk="657"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="78" subjects_affected="68" subjects_at_risk="657"/>
                <counts group_id="E2" events="48" subjects_affected="43" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="37" subjects_affected="33" subjects_at_risk="657"/>
                <counts group_id="E2" events="31" subjects_affected="22" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="72" subjects_affected="66" subjects_at_risk="657"/>
                <counts group_id="E2" events="45" subjects_affected="38" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="110" subjects_affected="89" subjects_at_risk="657"/>
                <counts group_id="E2" events="84" subjects_affected="74" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="38" subjects_affected="33" subjects_at_risk="657"/>
                <counts group_id="E2" events="36" subjects_affected="33" subjects_at_risk="554"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="64" subjects_affected="57" subjects_at_risk="657"/>
                <counts group_id="E2" events="52" subjects_affected="48" subjects_at_risk="554"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/ presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

